Federated Hermes
KALV

Federated Hermes’s KalVista Pharmaceuticals KALV Stock Holding History

Federated Hermes’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-3,719
Closed -$74.9K – 2114
2026
Q1 		$74.9K Buy
3,719
+3,644
+4,859% +$58.7K ﹤0.01% 1633
2025
Q4 		$1.21K Buy
+75
New +$993 ﹤0.01% 2008
2021
Q3 		– Sell
-39
Closed -$1K – 2274
2021
Q2 		$1K Hold
39
– – ﹤0.01% 2136
2021
Q1 		$1K Buy
+39
New +$1.02K ﹤0.01% 2172
2020
Q2 		– Sell
-266
Closed -$2K – 2307
2020
Q1 		$2K Buy
+266
New +$3.59K ﹤0.01% 2019
2019
Q2 		– Sell
-491
Closed -$14K – 2187
2019
Q1 		$14K Buy
491
+205
+72% +$4.44K ﹤0.01% 1821
2018
Q4 		$6K Buy
286
+138
+93% +$2.77K ﹤0.01% 1950
2018
Q3 		$3K Buy
+148
New +$2K ﹤0.01% 2112
2018
Q2 		– Sell
-503
Closed -$5K – 2241
2018
Q1 		$5K Buy
+503
New +$5.27K ﹤0.01% 1964

Other funds holding KALV

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Federated Hermes's KALV Position: Q2 2026 in Review

Federated Hermes sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 3,719 shares — an estimated $74.9K sold.

Federated Hermes first reported a position in KALV in Q1 2018 and held it in 9 quarters. The position peaked at $74.9K in Q1 2026. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.

  • Federated Hermes reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Federated Hermes sold 3,719 KalVista Pharmaceuticals shares in Q2 2026, an estimated $74.9K.
  • Federated Hermes first reported a position in KalVista Pharmaceuticals in Q1 2018 and held it in 9 quarters.
  • Federated Hermes's KalVista Pharmaceuticals position peaked at $74.9K in Q1 2026.
  • 1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.

Based on Federated Hermes's 13F filing for Q2 2026, filed 12 Aug 2026.